CT 1530

Drug Profile

CT 1530

Alternative Names: CT-1530

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Xilintai Pharmaceutical
  • Developer Centaurus Biopharma
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic lymphocytic leukaemia

Most Recent Events

  • 12 Dec 2016 Preclinical trials in Chronic lymphocytic leukaemia in China (unspecified route)
  • 12 Dec 2016 Centaurus Biopharma plans a phase I trial for Chronic lymphocytic leukaemia, non-Hodgkin's lymphoma and Waldenstrom's macroglobulinemia in China (NCT02981745)
  • 01 Aug 2016 CFDA approves IND application for CT 1530 in Chronic lymphocytic leukaemia (Centaurus Biopharma website, December 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top